Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.30 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921362 | 0.88 | CSNK2A1 (0.43) | CSNK2A1CYP1A2GSK3B | |
| SCHEMBL29351558 | 0.88 | CSNK2A1 (0.43) | CSNK2A1CYP1A2GSK3BPRKAB2PRKAG1 | |
| SCHEMBL307261 | 0.88 | CSNK2A1 (0.43) | CSNK2A1CYP1A2GSK3BPRKAB2PRKAG1 | |
| SCHEMBL5175862 | 0.85 | CSNK2A1 (0.42) | CSNK2A1CYP1A2GSK3BPRKAB2PRKAG1 | |
| SCHEMBL6930060 | 0.78 | CSNK2A1 (0.46) | CSNK2A1CYP1A2GSK3BGPR84PRKAB2 | |
| SCHEMBL30712037 | 0.76 | PRKAB2 (0.37) | CSNK2A1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2124028 | 0.76 | PRKAB2 (0.37) | CSNK2A1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL6930062 | 0.76 | SLC22A6 (0.51) | CSNK2A1CYP1A2GSK3BPRKAB2PRKAG1 | |
| SCHEMBL2536803 | 0.76 | SLC22A6 (0.51) | CSNK2A1CYP1A2GSK3BPRKAB2PRKAG1 | |
| SCHEMBL305771 | 0.74 | GPR84 (0.49) | GSK3BGPR84SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181330-B2 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2016-08-31 | — | — | EP | claimed |
| EP-2181330-B1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2013-11-20 | — | — | EP | claimed |
| EP-1756295-B1 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2011-08-10 | — | — | EP | claimed |
| EP-1756567-B1 | BIOLOGICAL SOIL DETECTOR | 3M INNOVATIVE PROPERTIES CO (US) | 2011-06-22 | — | — | EP | claimed |
| JP-4658962-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-7524673-B2 | Biological soil detector | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-04-28 | — | — | US | claimed |
| US-7514235-B2 | Medium for identification of Candida | OXOID LIMITED (GB) | 2009-04-07 | — | — | US | claimed |
| EP-1692306-B1 | MEDIUM FOR IDENTIFICATION OF MICRO-ORGANISMS | OXOID LTD (GB) | 2009-01-14 | — | — | EP | claimed |
| US-7465536-B2 | solid support member; a specific indicator immobilized on the solid support member; and a retaining member which holds the solid support, the retaining member and solid support are configured so that the solid support will readily contact a surface being tested for the presence of biological soil | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-12-16 | — | — | US | claimed |
| JP-2007534309-A | — | — | 2007-11-29 | — | — | JP | claimed |
| US-20070218521-A1 | Medium For Identification Of Micro-Organisms | OXOID LIMITED (GB) | 2007-09-20 | — | — | US | claimed |
| EP-1756567-A2 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M Innovative Properties Company (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1756295-A1 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M Innovative Properties Company (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1692306-A1 | MEDIUM FOR IDENTIFICATION OF MICRO-ORGANISMS | Oxoid Limited (GB) | 2006-08-23 | — | — | EP | claimed |
| WO-2005113796-A1 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-01 | — | — | WO | claimed |
| WO-2005114184-A2 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050250169-A1 | Biological soil detector and method of using same | 3M INNOVATIVE PROPERTIES COMPANY | 2005-11-10 | — | — | US | claimed |
| US-20050250168-A1 | Biological soil detector and method of using same | 3M INNOVATIVE PROPERTIES COMPANY | 2005-11-10 | — | — | US | claimed |
| WO-2005059169-A1 | MEDIUM FOR IDENTIFICATION OF MICRO-ORGANISMS | OXOID LIMITED (GB) | 2005-06-30 | — | — | WO | claimed |
| US-20260132214-A1 | GLYPICAN 3 ANTIBODY AND RELATED METHODS | JECHO LABORATORIES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4733317-A2 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MedImmune, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4724099-A2 | INTERLEUKIN-15 FUSION PROTEIN AND METHODS OF USE | Jecho Laboratories, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3169407-B1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MEDIMMUNE LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12492240-B2 | Neutralizing anti-influenza A antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-12487180-B2 | Device and methods for quantifying analytes introduction | Life Technologies Corporation (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4626930-A2 | ANTI-MESOTHELIN BISPECIFIC ANTIBODIES AND METHODS OF USE | Jecho Laboratories, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302952-A1 | METHOD OF TREATING INFLUENZA A | MEDIMMUNE, LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250263470-A1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MEDIMMUNE LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12391768-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-4598961-A1 | GLYPICAN 3 ANTIBODY AND RELATED METHODS | Jecho Laboratories, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12357692-B2 | Method of treating influenza A | MEDIMMUNE, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4565237-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA | Chimerix, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12325740-B2 | Neutralizing anti-influenza B antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250152728-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-15 | — | — | US | disclosed |
| CN-119997956-A | Pharmaceutical composition and use thereof for treating glioma | 奇默里克斯公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025085590-A1 | MULTIFUNCTIONAL PD1 FUSION PROTEINS | Jecho Laboratories, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4524567-A2 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | Oncoceutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119161468-A | Neutralizing anti-influenza b antibodies and uses thereof | 免疫医疗有限责任公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024253944-A2 | INTERLEUKIN-15 FUSION PROTEIN AND METHODS OF USE | Jecho Laboratories, Inc. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240366613-A1 | IMPRIDONES FOR GLIOMAS | ONCOCEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-113173990-B | Neutralizing anti-influenza b antibodies and uses thereof | 免疫医疗有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12102639-B2 | Imipridones for gliomas | ONCOCEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-113563462-B | Neutralizing anti-influenza b antibodies and uses thereof | 免疫医疗有限责任公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-113667012-B | Neutralizing anti-influenza A antibodies and uses thereof | 免疫医疗有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240209067-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | MEDIMMUNE, LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2024119065-A2 | ANTI-MESOTHELIN BISPECIFIC ANTIBODIES AND METHODS OF USE | Jecho Laboratories, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-118005782-A | Neutralizing anti-influenza a antibodies and uses thereof | 免疫医疗有限责任公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024076375-A1 | GLYPICAN 3 ANTIBODY AND RELATED METHODS | Jecho Laboratories, Inc. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-113667013-B | Neutralizing anti-influenza A antibodies and uses thereof | 免疫医疗有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240101712-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LTD (GB) | 2024-03-28 | — | — | US | disclosed |
| US-20240092851-A1 | IL-7 FUSION PROTEIN AND RELATED METHODS | JECHO LABORATORIES INC (US) | 2024-03-21 | — | — | US | disclosed |
| US-11932682-B2 | Neutralizing anti-influenza A antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240076357-A1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | HUMABS BIOMED SA (CH) | 2024-03-07 | — | — | US | disclosed |
| CN-106922129-B | Methods of conjugating polypeptides | 免疫医疗有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024035787-A2 | CLAUDIN-6 ANTIBODIES AND CONJUGATES THEREOF AND USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024030645-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA | CHIMERIX, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-3200829-B1 | METHOD OF CONJUGATING A POLYPEPTIDE | MEDIMMUNE LLC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230384227-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES INTRODUCTION | INVITROGEN CORPORATION | 2023-11-30 | — | — | US | disclosed |
| EP-3443126-B1 | TISSUE PROFILING USING MULTIPLEXED IMMUNOHISTOCHEMICAL CONSECUTIVE STAINING | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11787853-B2 | Neutralizing anti-influenza b antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| EP-4251186-A1 | IL-7 FUSION PROTEIN AND RELATED METHODS | Jecho Laboratories, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11773186-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11753676-B2 | Multiplexed in situ hybridization of tissue sections for spatially resolved transcriptomics with expansion microscopy | EXPANSION TECHNOLOGIES (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | EXPANSION TECHNOLOGIES (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116685345-A | IL-7 fusion proteins and related methods | 杰科生物医药公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-116271017-A | Methods of treating influenza A | 免疫医疗有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230181735-A1 | METHOD OF TREATING INFLUENZA A | MEDIMMUNE LLC (US) | 2023-06-15 | — | — | US | disclosed |
| CN-219142860-U | Enzyme detection card structure with accurate contrast | 广州新原生物科技有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116173036-A | E Mi Litong for glioma | 昂克希尔迪克斯有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-108290952-B | Compositions and methods for inhibiting cancer stem cells | 免疫医疗有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11639342-B2 | 1,3-dipolar cycloadditions, and Staudinger ligations for conjugating biomolecules using click chemistry | Bioconjugate Technologies, LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11635383-B2 | Device and methods for quantifying analytes introduction | INVITROGEN CORPORATION | 2023-04-25 | — | — | US | disclosed |
| CN-115844895-A | Use of an emiritone compound for the preparation of a medicament for the treatment of central nervous system cancer | 昂克希尔迪克斯有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230042563-A1 | IMMUNOCHROMATOGRAPHIC STRIP, IMMUNOCHROMATOGRAPHIC DEVICE, IMMUNOCHROMATOGRAPHIC KIT, AND METHOD FOR DETECTING TEST SUBSTANCE | FUJIREBIO INC. (JP) | 2023-02-09 | — | — | US | disclosed |
| CN-109311980-B | G protein-coupled receptor (GPCR) modulation by emilienone (IMIPRIDONES) | 昂克希尔迪克斯有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-11547756-B2 | Method of treating influenza A | MEDIMMUNE, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| CN-115515429-A | Chewable matrices and their use for collecting saliva samples and for infection detection | WM.雷格利 JR.公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4092418-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | Life Technologies Corporation (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-4083625-A1 | IMMUNOCHROMATOGRAPHIC STRIP, IMMUNOCHROMATOGRAPHIC DEVICE, IMMUNOCHROMATOGRAPHIC KIT, AND METHOD FOR DETECTING TEST SUBSTANCE | Fujirebio Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-11479811-B2 | Expansion microscopy compatible and multiplexed in situ hybridization of formalin fixed paraffin embedded tissue sections for spatially resolved transcriptomics | EXPANSION TECHNOLOGIES (US) | 2022-10-25 | — | — | US | disclosed |
| US-11414477-B2 | Methods for preparing antibodies with a defined glycosylation pattern | MEDIMMUNE, LLC (US) | 2022-08-16 | — | — | US | disclosed |
| CN-107847764-B | Compositions and methods for treating cancer | 免疫医疗有限责任公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220195037-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS | MEDIMMUNE LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| WO-2022115396-A1 | IL-7 FUSION PROTEIN AND RELATED METHODS | Jecho Laboratories, Inc. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220160882-A1 | METHOD OF CONJUGATING A POLYPEPTIDE | MEDIMMUNE, LLC | 2022-05-26 | — | — | US | disclosed |
| CN-114441763-A | Detection method of interleukin 2 | 江苏恒瑞医药股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3438131-B1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | LIFE TECHNOLOGIES CORP (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220072001-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-03-10 | — | — | US | disclosed |
| US-20220042915-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES INTRODUCTION | INVITROGEN CORPORATION | 2022-02-10 | — | — | US | disclosed |
| US-20220033480-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | MEDIMMUNE LLC | 2022-02-03 | — | — | US | disclosed |
| US-20220025020-A1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MEDIMMUNE LLC | 2022-01-27 | — | — | US | disclosed |
| CN-113956361-A | Antibodies to ticagrelor and methods of use thereof | 免疫医疗有限公司 | 2022-01-21 | — | — | CN | disclosed |
| EP-1991273-B2 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | LIFE TECHNOLOGIES CORP (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210380673-A1 | Compositions And Methods For Treating Cancer | MEDIMMUNE, LLC | 2021-12-09 | — | — | US | disclosed |
| US-11192948-B2 | Compositions and methods for inhibiting cancer stem cells | MEDIMMUNE LIMITED (GB) | 2021-12-07 | — | — | US | disclosed |
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LTD (GB) | 2021-12-02 | — | — | US | disclosed |
| US-11186627-B2 | Neutralizing anti-influenza A antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2021-11-30 | — | — | US | disclosed |
| WO-2021237051-A1 | SARS-CoV-2 ANTIBODY AND RELATED METHODS | Jecho Laboratories, Inc. (US) | 2021-11-25 | — | — | WO | disclosed |
| CN-106715473-B | Antibodies to ticagrelor and methods of use thereof | 免疫医疗有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113667012-A | Neutralizing anti-influenza a antibodies and uses thereof | 免疫医疗有限责任公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113667013-A | Neutralizing anti-influenza a antibodies and uses thereof | 免疫医疗有限责任公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11174304-B2 | Neutralizing anti-influenza B antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| CN-113563462-A | Neutralizing anti-influenza b antibodies and uses thereof | 免疫医疗有限责任公司 | 2021-10-29 | — | — | CN | disclosed |
| US-11116771-B2 | G protein-coupled receptor (GPCR) modulation by imipridones | ONCOCEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| CN-105848722-B | Neutralizing anti-influenza a antibodies and uses thereof | 免疫医疗有限责任公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210236499-A1 | IMIPRIDONES FOR GLIOMAS | ONCOCEUTICS, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| CN-113173990-A | Neutralizing anti-influenza b antibodies and uses thereof | 免疫医疗有限责任公司 | 2021-07-27 | — | — | CN | disclosed |
| US-11067580-B2 | Compounds and methods for conjugation of biomolecules | Life Technologies Corporation (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210215580-A1 | COMBINING MODIFIED ANTIBODIES WITH EXPANSION MICROSCOPY FOR IN-SITU, SPATIALLY-RESOLVED PROTEOMICS | EXPANSION TECHNOLOGIES (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214338-A1 | 1,3-DIPOLAR CYCLOADDITIONS, AND STAUDINGER LIGATIONS FOR CONJUGATING BIOMOLECULES USING CLICK CHEMISTRY | Bioconjugate Technologies, LLC (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214419-A1 | METHODS FOR PREPARING ANTIBODIES WITH A DEFINED GLYCOSYLATION PATTERN | MEDIMMUNE, LLC | 2021-07-15 | — | — | US | disclosed |
| CN-106573154-B | Neutralizing anti-influenza b antibodies and uses thereof | 免疫医疗有限责任公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-106459205-B | Conjugated compounds comprising cysteine engineered antibodies | 免疫医疗有限责任公司 | 2021-04-09 | — | — | CN | disclosed |
| US-10962480-B2 | Device and methods for quantifying analytes introduction | Life Technologies Corporation (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3322484-B1 | METHOD FOR DETECTING CANCER STEM CELLS | MEDIMMUNE LLC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10946022-B2 | Imipridones for gliomas | ONCOCEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069341-A1 | CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES | MEDIMMUNE, LLC | 2021-03-11 | — | — | US | disclosed |
| US-20200397899-A1 | METHOD OF TREATING INFLUENZA A | MEDIMMUNE, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20200354782-A1 | EXPANSION MICROSCOPY COMPATIBLE AND MULTIPLEXED IN SITU HYBRIDIZATION OF FORMALIN FIXED PARAFFIN EMBEDDED TISSUE SECTIONS FOR SPATIALLY RESOLVED TRANSCRIPTOMICS | EXPANSION TECHNOLOGIES (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3733244-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | Medlmmune, LLC (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111818919-A | Imipritone for glioma | 昂克希尔迪克斯有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200333351-A1 | Compounds and Methods for Conjugation of Biomolecules | Life Technologies Corporation | 2020-10-22 | — | — | US | disclosed |
| US-20200292456-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES INTRODUCTION | Life Technologies Corporation | 2020-09-17 | — | — | US | disclosed |
| EP-3703681-A1 | IMIPRIDONES FOR GLIOMAS | Oncoceutics, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10744204-B2 | Conjugated compounds comprising cysteine-engineered antibodies | MEDIMMUNE, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200239946-A1 | MULTIPLEXED IN SITU HYBRIDIZATION OF TISSUE SECTIONS FOR SPATIALLY RESOLVED TRANSCRIPTOMICS WITH EXPANSION MICROSCOPY | EXPANSION TECHNOLOGIES (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200216871-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION | 2020-07-09 | — | — | US | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
| EP-3052192-B1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | MEDIMMUNE LLC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190169-A1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | HUMABS BIOMED SA (CH) | 2020-06-18 | — | — | US | disclosed |
| US-10676771-B2 | Oligosaccharide modification and labeling of proteins | Life Technologies Corporation (US) | 2020-06-09 | — | — | US | disclosed |
| US-10648985-B2 | Compounds and methods for conjugation of biomolecules | Life Technologies Corporation (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111108187-A | Culture medium for selectively isolating Clostridium bacteria | 捷恩智株式会社 | 2020-05-05 | — | — | CN | disclosed |
| US-20200109188-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | HUMABS BIOMED SA (CH) | 2020-04-09 | — | — | US | disclosed |
| EP-3630732-A1 | METHOD AND MOLECULES | Medimmune, LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102382-A1 | Compositions And Methods For Treating Cancer | MEDIMMUNE, LLC | 2020-04-02 | — | — | US | disclosed |
| US-10494419-B2 | Neutralizing anti-influenza A antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2019-12-03 | — | — | US | disclosed |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20190307751-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | ONCOCEUTICS, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-2776061-B1 | MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF | MEDIMMUNE LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10369154-B2 | Imipridones for gliomas | ONCOCEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190233504-A1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | HUMABS BIOMED SA (CH) | 2019-08-01 | — | — | US | disclosed |
| US-20190183895-A1 | IMIPRIDONES FOR GLIOMAS | ONCOCEUTICS, INC. (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2019103996-A1 | EXPANSION MICROSCOPY COMPATIBLE AND MULTIPLEXED IN SITU HYBRIDIZATION OF FORMALIN FIXED PARAFFIN EMBEDDED TISSUE SECTIONS FOR SPATIALLY RESOLVED TRANSCRIPTOMICS | EXPANSION TECHNOLOGIES (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190154696-A1 | Colorimetric Labeling and Detection Methods and Compositions | Life Technologies Corporation | 2019-05-23 | — | — | US | disclosed |
| US-10294292-B2 | Neutralizing anti-influenza B antibodies and uses thereof | HUMABS BIOMED SA (CH) | 2019-05-21 | — | — | US | disclosed |
| EP-2535423-B1 | Labeling and detection of nucleic acids | LIFE TECHNOLOGIES CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2877483-B1 | TARGETED DELIVERY OF REAGENTS THROUGH PATTERNED TRANSFER SHEETS | BIO RAD LABORATORIES (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190120845-A1 | TISSUE PROFILING USING MULTIPLEXED IMMUNOHISTOCHEMICAL CONSECUTIVE STAINING | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-04-25 | — | — | US | disclosed |
| WO-2019075091-A1 | MULTIPLEXED IN SITU HYBRIDIZATION OF TISSUE SECTIONS FOR SPATIALLY RESOLVED TRANSCRIPTOMICS WITH EXPANSION MICROSCOPY | EXPANSION TECHNOLOGIES (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190079095-A1 | COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES | Life Technologies Corporation | 2019-03-14 | — | — | US | disclosed |
| US-20190077882-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2019-03-14 | — | — | US | disclosed |
| EP-3443126-A1 | TISSUE PROFILING USING MULTIPLEXED IMMUNOHISTOCHEMICAL CONSECUTIVE STAINING | Icahn School of Medicine at Mount Sinai (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3438131-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | Life Technologies Corporation (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015509-A1 | METHOD OF TREATING INFLUENZA A | MEDIMMUNE, LLC | 2019-01-17 | — | — | US | disclosed |
| EP-3129406-B1 | CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES | MEDIMMUNE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-10172862-B2 | Imipridones for gliomas | ONCOCEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3407914-A1 | METHODS FOR PREPARING ANTIBODIES WITH A DEFINED GLYCOSYLATION PATTERN | MedImmune, LLC (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3408298-A2 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | Oncoceutics, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| WO-2018218093-A1 | METHOD AND MOLECULES | MEDIMMUNE, LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180335386-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES | INVITROGEN CORPORATION | 2018-11-22 | — | — | US | disclosed |
| EP-3402513-A1 | METHOD OF TREATING INFLUENZA A | MedImmune, LLC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180319897-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20180273616-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS | MEDIMMUNE LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| US-20180237515-A1 | Compositions And Methods For Treating Cancer | MEDIMMUNE, LLC | 2018-08-23 | — | — | US | disclosed |
| US-20180221375-A1 | IMIPRIDONES FOR GLIOMAS | ONCOCEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| EP-1987068-B1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | LIFE TECHNOLOGIES CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356414-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS | Medimmune Limited (GB) | 2018-08-08 | — | — | EP | disclosed |
| EP-3344782-A1 | COLORIMETRIC LABELING AND DETECTION METHODS AND COMPOSITIONS | Life Technologies Corporation (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20180169255-A1 | CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES | MEDIMMUNE, LLC | 2018-06-21 | — | — | US | disclosed |
| US-9982061-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| EP-3322484-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Medimmune, LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9964490-B2 | Device and methods for quantifying analytes | Life Technologies Corporation (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180052081-A1 | COMBINING MODIFIED ANTIBODIES WITH EXPANSION MICROSCOPY FOR IN-SITU, SPATIALLY-RESOLVED PROTEOMICS | EXPANSION TECHNOLOGIES (US) | 2018-02-22 | — | — | US | disclosed |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2017-12-21 | — | — | US | disclosed |
| US-20170304460-A1 | METHOD OF CONJUGATING A POLYPEPTIDE | MEDIMMUNE, LLC | 2017-10-26 | — | — | US | disclosed |
| WO-2017181176-A1 | TISSUE PROFILING USING MULTIPLEXED IMMUNOHISTOCHEMICAL CONSECUTIVE STAINING | LCAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170253918-A1 | COMBINING PROTEIN BARCODING WITH EXPANSION MICROSCOPY FOR IN-SITU, SPATIALLY-RESOLVED PROTEOMICS | EXPANSION TECHNOLOGIES | 2017-09-07 | — | — | US | disclosed |
| US-20170241947-A1 | TARGETED DELIVERY OF REAGENTS TO SPOTS ON A PLANAR SUPPORT THROUGH PATTERNED TRANSFER SHEETS | BIO-RAD LABORATORIES, INC. | 2017-08-24 | — | — | US | disclosed |
| EP-3200829-A1 | METHOD OF CONJUGATING A POLYPEPTIDE | Medimmune, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3201235-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | Medimmune Limited (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-20170218054-A1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | HUMABS BIOMED SA (CH) | 2017-08-03 | — | — | US | disclosed |
| WO-2017132298-A1 | METHODS FOR PREPARING ANTIBODIES WITH A DEFINED GLYCOSYLATION PATTERN | MEDIMMUNE, LLC (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132661-A2 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | ONCOCEUTICS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017123685-A1 | METHOD OF TREATING INFLUENZA A | MEDIMMUNE, LLC (US) | 2017-07-20 | — | — | WO | disclosed |
| US-20170183408-A1 | ANTIBODY SCAFFOLD FOR HOMOGENOUS CONJUGATION | MEDIMMUNE LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170166943-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | INVITROGEN CORPORATION | 2017-06-15 | — | — | US | disclosed |
| EP-2623986-B1 | Labeling and detection of post translationally modified proteins | LIFE TECHNOLOGIES CORP (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3169407-A2 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | Medimmune, LLC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9645140-B2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2017-05-09 | — | — | US | disclosed |
| US-9645153-B2 | Labeling reagents and methods of their use | Life Technologies Corporation (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2966061-B1 | COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES | LIFE TECHNOLOGIES CORP (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114151-A1 | MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF | MEDIMMUNE LLC | 2017-04-27 | — | — | US | disclosed |
| US-9594054-B2 | Targeted delivery of reagents to spots on a planar support through patterned transfer sheets | BIO-RAD LABORATORIES, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2017040510-A1 | COLORIMETRIC LABELING AND DETECTION METHODS AND COMPOSITIONS | Life Technologies Corporation (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9580509-B2 | Multispecific and multivalent binding proteins and uses thereof | MEDIMMUNE, LLC (US) | 2017-02-28 | — | — | US | disclosed |
| EP-3129406-A1 | CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES | Medimmune, LLC (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2017011559-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MEDLMMUNE, LLC (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-2623609-B1 | Labeling and detection of post translationally modified proteins | LIFE TECHNOLOGIES CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160257732-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | HUMABS BIOMED SA (CH) | 2016-09-08 | — | — | US | disclosed |
| EP-2181330-B2 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2016-08-31 | — | — | EP | disclosed |
| EP-3052192-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | MedImmune, LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160177370-A1 | METHOD FOR DETECTING STREPTOCOCCUS AGALACTIAE USING ESTERASE ACTIVITY | BIOMERIEUX SA (FR) | 2016-06-23 | — | — | US | disclosed |
| US-20160130366-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-9309552-B2 | Method for detecting Streptococcus agalactiae using esterase activity | BIOMERIEUX (FR) | 2016-04-12 | — | — | US | disclosed |
| WO-2016050867-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054315-A1 | METHOD OF CONJUGATING A POLYPEPTIDE | MEDIMMUNE, LLC (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015050959-A9 | ANTI-KIT ANTIBODIES AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016011035-A2 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MEDLMMUNE, LLC (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-2966061-A1 | COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES | Life Technologies Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160003743-A1 | Device and Methods for Quantifying Analytes | INVITROGEN CORPORATION | 2016-01-07 | — | — | US | disclosed |
| US-20150355186-A1 | Labeling Reagents and Methods of Their Use | INVITROGEN CORPORATION | 2015-12-10 | — | — | US | disclosed |
| WO-2015157595-A1 | CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES | MEDIMMUNE, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| US-9140706-B2 | Labeling reagents and methods of their use | Life Technologies Corporation (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2681196-B1 | COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES | LIFE TECHNOLOGIES CORP (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2877483-A1 | TARGETED DELIVERY OF REAGENTS THROUGH PATTERNED TRANSFER SHEETS | Bio-rad Laboratories, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20150132320-A1 | MUTATED ANTI-TNFa ANTIBODIES AND METHODS OF THEIR USE | ABBVIE, INC. | 2015-05-14 | — | — | US | disclosed |
| EP-2623610-B1 | Labeling and detection of post translationally modified proteins | LIFE TECHNOLOGIES CORP (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2516386-B1 | PROTEIN MODIFICATION FROM THE OXIDATION OF CLICKABLE POLYUNSATURATED FATTY ACID ANALOGS | LIFE TECHNOLOGIES CORP (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2015051010-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | MEDIMMUNE, LLC (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015050959-A1 | ANTI-KIT ANTIBODIES AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150072396-A1 | Compounds and Methods for Conjugation of Biomolecules | Life Technologies Corporation (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150051096-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2015-02-19 | — | — | US | disclosed |
| US-20150004629-A1 | Thermostable Proteins and Methods of Making and Using Thereof | BECTON, DICKINSON AND COMPANY (US) | 2015-01-01 | — | — | US | disclosed |
| US-8921526-B2 | Mutated anti-TNFα antibodies and methods of their use | ABBVIE, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140377837-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | LIFE TECHNOLOGIES CORP (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140336079-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | LIFE TECHNOLOGIES CORP (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140314784-A1 | ANTI-CXCR4 ANTIBODIES AND METHODS OF USE | MEDLMMUNE LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140302038-A1 | MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF | MEDIMMUNE, LLC | 2014-10-09 | — | — | US | disclosed |
| WO-2014159579-A1 | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140271626-A1 | MUTATED ANTI-TNFa ANTIBODIES AND METHODS OF THEIR USE | ABBVIE, INC. | 2014-09-18 | — | — | US | disclosed |
| EP-2776061-A1 | MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF | MedImmune, LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140206848-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | Life Technologies Corporation (US) | 2014-07-24 | — | — | US | disclosed |
| US-8785212-B2 | Oligosaccharide modification and labeling of proteins | Life Technologies Corporation (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778635-B2 | Thermostable proteins and methods making and using thereof | BECTON, DICKINSON AND COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2487235-B1 | Medium for detecting Streptococcus agalatiae using esterase activity | BIOMERIEUX SA (FR) | 2014-07-02 | — | — | EP | disclosed |
| US-20140155581-A1 | Methods For Making Multimeric Polypeptides | MEDIMMUNE, LLC | 2014-06-05 | — | — | US | disclosed |
| EP-2734234-A2 | ANTI-CXCR4 ANTIBODIES AND METHODS OF USE | Medimmune Limited (GB) | 2014-05-28 | — | — | EP | disclosed |
| WO-2011139974-A9 | ANTI-PAI-1 ANTIBODIES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-2729488-A1 | METHODS FOR MAKING MULTIMERIC POLYPEPTIDES | MedImmune, LLC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8716033-B2 | Oligosaccharide modification and labeling of proteins | Life Technologies Corporation (US) | 2014-05-06 | — | — | US | disclosed |
| US-8680320-B2 | Heavy metal binding compounds and their method of use | Life Technologies Corporation (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140027284-A1 | TARGETED DELIVERY OF REAGENTS TO SPOTS ON A PLANAR SUPPORT THROUGH PATTERNED TRANSFER SHEETS | BIO-RAD LABORATORIES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014018721-A1 | TARGETED DELIVERY OF REAGENTS THROUGH PATTERNED TRANSFER SHEETS | BIO-RAD LABORATORIES, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-2681196-A1 | COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES | Life Technologies Corporation (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8623282-B2 | Device and methods for quantifying analytes | Life Technologies Corporation (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623639-B2 | Thermostable proteins and methods of making and using thereof | BECTON, DICKINSON AND COMPANY (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130337536-A1 | Labeling Reagents and Methods of Their Use | Life Technologies Corporation (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130330350-A1 | Antibody Scaffold For Homogenous Conjugation | MEDIMMUNE, LLC (US) | 2013-12-12 | — | — | US | disclosed |
| US-8604243-B2 | Fluorescent ion indicators for cadmium and lanthanide ion detection | Life Technologies Corporation (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2181330-B1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2013-11-20 | — | — | EP | disclosed |
| US-8586743-B2 | Labeling reagents and methods of their use | Life Technologies Corporation (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130302908-A1 | Thermostable Proteins and Methods Making and Using Thereof | BECTON, DICKINSON AND COMPANY | 2013-11-14 | — | — | US | disclosed |
| US-20130266566-A1 | METHODS OF INHIBITING FIBROSIS USING ANTI-PAI-1 ANTIBODIES | ABBOTT LABORATORIES (US) | 2013-10-10 | — | — | US | disclosed |
| US-8551408-B2 | Device and methods for quantifying analytes | Life Technologies Corporation (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2638066-A2 | ANTIBODY SCAFFOLD FOR HOMOGENOUS CONJUGATION | MedImmune, LLC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8535894-B2 | Antibody complexes and methods for immunolabeling | Life Technologies Corporation (US) | 2013-09-17 | — | — | US | disclosed |
| EP-1934607-B1 | MULTIPLEX IN SITU IMMUNOHISTOCHEMICAL ANALYSIS | FUNDACAO D ANNA SOMMER CHAMPALIMAUD E DR CARLOS MONTEZ CHAMPALIMAUD (PT) | 2013-08-28 | — | — | EP | disclosed |
| EP-2623609-A2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623986-A2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623610-A2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-1991273-B1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | LIFE TECHNOLOGIES CORP (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8445702-B2 | Zinc binding compounds and their method of use | Life Technologies Corporation (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2013070565-A1 | MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF | MEDIMMUNE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130089884-A1 | Protein Modification from the Oxidation of Clickable Polyunsaturated Fatty Acid Analogs | Life Technologies Corporation (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130072666-A1 | Antibody Complexes and Methods for Immunolabeling | Life Technologies Corporation (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2566890-A2 | ANTI-PAI-1 ANTIBODIES AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2566514-A2 | METHODS OF INHIBITING FIBROSIS USING ANTI-PAI-1 ANTIBODIES | AbbVie Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130035249-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CEA-EXPRESSING CANCERS | MEDIMMUNE, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2013013025-A2 | ANTI-CXCR4 ANTIBODIES AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2013-01-24 | — | — | WO | disclosed |
| US-20130017154-A1 | Uniform Fluorescent Microsphere with Hydrophobic Surfaces | Life Technologies Corporation (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130011829-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES | Life Technologies Corporation (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2013006544-A1 | METHODS FOR MAKING MULTIMERIC POLYPEPTIDES | MEDIMMUNE, LLC (US) | 2013-01-10 | — | — | WO | disclosed |
| EP-2535423-A2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2224013-B1 | Methods for the determination of telomerase activity using click chemistry | LIFE TECHNOLOGIES CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8323903-B2 | Detection of preferential target in sample; obtain sample, mix with labelled antibody, detect presence of label, the presence of label indicates presence of target | Life Technologies Corporation (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120301894-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012155049-A1 | TREATMENT OF LUNG INFLAMMATION | MEDIMMUNE, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| US-8304195-B2 | Antibody complexes and methods for immunolabeling | Life Technologies Corporation (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2516386-A2 | PROTEIN MODIFICATION FROM THE OXIDATION OF CLICKABLE POLYUNSATURATED FATTY ACID ANALOGS | Life Technologies Corporation (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2507628-A1 | IMPROVED METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CEA-EXPRESSING CANCERS | MedImmune, LLC (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012121973-A1 | COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES | Life Technologies Corporation (US) | 2012-09-13 | — | — | WO | disclosed |
| EP-1789575-B1 | METHOD FOR DETECTING STREPTOCOCCUS AGALACTIAE USING ESTERASE ACTIVITY | BIOMERIEUX SA (FR) | 2012-09-05 | — | — | EP | disclosed |
| EP-2029799-B1 | THERMOSTABLE PROTEINS AND METHODS OF MAKING AND USING THEREOF | BECTON DICKINSON CO (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2487235-A1 | Medium for detecting streptococcus agalactiae using esterase activity | bioMérieux (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-8227194-B2 | Monoclonal antibodies with binding specificity for response gene to complement 32 (RGC-32) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012088247-A2 | ANTI-C5/C5A/C5ADESR ANTIBODIES AND FRAGMENTS | MEDIMMUNE, LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-2113773-B1 | Antibody complexes | LIFE TECHNOLOGIES CORP (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2259067-B1 | Methods for immunolabeling | LIFE TECHNOLOGIES CORP (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012064733-A2 | ANTIBODY SCAFFOLD FOR HOMOGENOUS CONJUGATION | MEDIMMUNE, LLC (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120114652-A1 | ANTI-PAI-1 ANTIBODIES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120107844-A1 | IMMUNOSORBENT ASSAY SUPPORT AND METHOD OF USE | Life Technologies Corporation (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120064012-A1 | Uniform Fluorescent Microspheres with Hydrophobic Surfaces | Life Technologies Corporation (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2012022734-A2 | ANTI-ICAM-1 ANTIBODIES AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| US-8114636-B2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-02-14 | — | — | US | disclosed |
| US-8093012-B2 | Multiplex in situ immunohistochemical analysis | AUREON LABORATORIES, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2011139974-A2 | ANTI-PAI-1 ANTIBODIES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139973-A2 | METHODS OF INHIBITING FIBROSIS USING ANTI-PAI-1 ANTIBODIES | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110207171-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | Life Technologies Corporation (US) | 2011-08-25 | — | — | US | disclosed |
| EP-1756295-B1 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011079188-A2 | PROTEIN MODIFICATION FROM THE OXIDATION OF CLICKABLE POLYUNSATURATED FATTY ACID ANALOGS | Life Technologies Corporation (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110159517-A1 | Zinc binding compounds and their method of use | Life Technologies Corporation (US) | 2011-06-30 | — | — | US | disclosed |
| EP-1756567-B1 | BIOLOGICAL SOIL DETECTOR | 3M INNOVATIVE PROPERTIES CO (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011068758-A1 | IMPROVED METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CEA-EXPRESSING CANCERS | MEDIMMUNE, LLC (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110034344-A1 | RESPONSE GENE TO COMPLEMENT 32 (RGC-32) IN DISEASE | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110021372-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | Life Technologies Corporation (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2259067-A2 | Methods for immunolabeling | Molecular Probes, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100273188-A1 | Serum Prolactin Binding Protein in Epithelial Carcinoma | Life Technologies Corporation (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100255601-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES | INVITROGEN CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2224013-A1 | Methods for the determination of telomerase activity using click chemistry | Life Technologies Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7776533-B2 | Compositions and methods for detection and isolation of phosphorylated molecules | Life Technologies Corporation (US) | 2010-08-17 | — | — | US | disclosed |
| US-7771928-B2 | Immunoassay device and immunoassay method using the same | FUJIREBIO INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20100167333-A1 | Heavy Metal Binding Compounds and Their Method of Use | Life Technologies Corporation (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167320-A1 | Compositions and Methods for Detecting and Quantifying Toxic Substances in Disease States | Life Technologies Corporation (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100068748-A1 | Fluorescent Ion Indicators for Cadmium and Lanthanide Ion Detection | INVITROGEN CORPORATION (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100009381-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | Life Technologies Corporation (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090298199-A1 | IMMUNOSORBENT ASSAY SUPPORT AND METHOD OF USE | Life Technologies Corporation (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2121718-A2 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090280108-A1 | SERUM AMYLOID A PROTEIN IN INFLAMMATION AND OBESITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-11-12 | — | — | US | disclosed |
| EP-2113773-A2 | Antibody complexes and methods for immunolabeling | Molecular Probes, Inc. (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090181364-A1 | ZINC BINDING COMPOUNDS AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| EP-1442302-B1 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | MOLECULAR PROBES INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090124511-A1 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | INVITROGEN CORPORATION (US) | 2009-05-14 | — | — | US | disclosed |
| US-7524673-B2 | Biological soil detector | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7521577-B2 | Heavy metal binding compounds and their method of use | MOLECULAR PROBES, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7514235-B2 | Medium for identification of Candida | OXOID LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1987361-A4 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES | INVITROGEN CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029799-A2 | THERMOSTABLE PROTEINS AND METHODS OF MAKING AND USING THEREOF | Becton, Dickinson and Company, Wagner, Jaconda (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1692306-B1 | MEDIUM FOR IDENTIFICATION OF MICRO-ORGANISMS | OXOID LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20090004753-A1 | LABELING REAGENTS AND METHODS OF THEIR USE | INVITROGEN CORPORATION (US) | 2009-01-01 | — | — | US | disclosed |
| US-7468272-B2 | Biological soil detector | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| US-7465536-B2 | solid support member; a specific indicator immobilized on the solid support member; and a retaining member which holds the solid support, the retaining member and solid support are configured so that the solid support will readily contact a surface being tested for the presence of biological soil | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1991273-A2 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Invitrogen Corporation (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1987361-A2 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES | INVITROGEN CORPORATION (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1987068-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | INVITROGEN CORPORATION (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7445894-B2 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1984724-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES | INVITROGEN CORPORATION (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1825265-A4 | SERUM AMYLOID A PROTEIN IN INFLAMMATION AND OBESITY | UNIV MARYLAND (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008101024-A2 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1934607-A1 | MULTIPLEX IN SITU IMMUNOHISTOCHEMICAL ANALYSIS | Aureon Laboratories, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008029281-A2 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080050731-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080044804-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | INVITROGEN CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080044856-A1 | THERMOSTABLE PROTEINS AND METHODS OF MAKING AND USING THEREOF | BECTON, DICKINSON AND COMPANY (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080038761-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080019921-A1 | UNIFORM FLUORESCENT MICROSPHERE WITH HYDROPHOBIC SURFACES | INVITROGEN CORPORATION (US) | 2008-01-24 | — | — | US | disclosed |
| US-20070269902-A1 | Antibody complexes and methods for immunolabeling | MOLECULAR PROBES, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070254326-A1 | Method for Detecting Streptococcus Agalactiae Using Esterase Activity | BIOMERIEUX (FR) | 2007-11-01 | — | — | US | disclosed |
| WO-2007124464-A2 | THERMOSTABLE PROTEINS AND METHODS OF MAKING AND USING THEREOF | BECTON, DICKINSON AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007090126-A9 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES | INVITROGEN CORP (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070218521-A1 | Medium For Identification Of Micro-Organisms | OXOID LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1825265-A2 | SERUM AMYLOID A PROTEIN IN INFLAMMATION AND OBESITY | University of Maryland, Baltimore (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007095506-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | INVITROGEN CORPORATION (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070190597-A1 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS | INVITROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007090126-A2 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES | INVITROGEN CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007087582-A1 | DEVICE AND METHODS FOR QUANTIFYING ANALYTES | INVITROGEN CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070161112-A1 | HEAVY METAL BINDING COMPOUNDS AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161055-A1 | IMMUNOSORBENT ASSAY SUPPORT AND METHOD OF USE | INVITROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070154958-A1 | Multiplex in situ immunohistochemical analysis | AUREON LABORATORIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007073562-A2 | FLUORESCENT ION INDICATORS FOR CADMIUM AND LANTHANIDE ION DETECTION | INVITROGEN CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007053837-A1 | AN IMMUNOSORBENT ASSAY SUPPORT AND METHOD OF USE | INVITROGEN CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007051112-A2 | SERUM PROLACTIN BINDING PROTEIN IN EPITHELIAL CARCINOMA | INVITROGEN CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070092920-A1 | Serum Prolactin Binding Protein in Epithelial Carcinoma | Life Technologies Corporation | 2007-04-26 | — | — | US | disclosed |
| WO-2007047450-A1 | MULTIPLEX IN SITU IMMUNOHISTOCHEMICAL ANALYSIS | AUREON LABORATORIES, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1442302-A4 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | MOLECULAR PROBES INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070054304-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | INVITROGEN CORPORATION (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1756567-A2 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M Innovative Properties Company (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756295-A1 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M Innovative Properties Company (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006108095-A9 | SERUM BIOMARKER FOR DISEASE AND METHODS OF USING SAME | UNIV MARYLAND (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006110748-A2 | RESPONSE GENE TO COMPLEMENT 32 (RGC-32) IN DISEASE | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108095-A2 | SERUM BIOMARKER FOR DISEASE AND METHODS OF USING SAME | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-10-12 | — | — | WO | disclosed |
| US-7102005-B2 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1692306-A1 | MEDIUM FOR IDENTIFICATION OF MICRO-ORGANISMS | Oxoid Limited (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20060160218-A1 | Transdifferentiation of cells and tissues | UNIVERSITY OF BATH, THE (GB) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063213-A2 | SERUM AMYLOID A PROTEIN IN INFLAMMATION AND OBESITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005113796-A1 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005114184-A2 | BIOLOGICAL SOIL DETECTOR AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050250214-A1 | Zinc binding compounds and their method of use | MOLECULAR PROBES, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050250169-A1 | Biological soil detector and method of using same | 3M INNOVATIVE PROPERTIES COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-20050250168-A1 | Biological soil detector and method of using same | 3M INNOVATIVE PROPERTIES COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-20050250089-A1 | Biological soil detector and method of using same | 3M INNOVATIVE PROPERTIES COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-20050250957-A1 | Compounds containing thiosulfate moieties | MOLECULAR PROBES, INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005059169-A1 | MEDIUM FOR IDENTIFICATION OF MICRO-ORGANISMS | OXOID LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| EP-1546118-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | Molecular Probes Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005047901-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION PHOSPHORYLATED MOLECULES | MOLECULAR PROBES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047242-A2 | COMPOUNDS CONTAINING THIOSULFATE MOIETIES | MOLECULAR PROBES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050069962-A1 | Antibody complexes and methods for immunolabeling | Life Technologies Corporation | 2005-03-31 | — | — | US | disclosed |
| US-20050014197-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. | 2005-01-20 | — | — | US | disclosed |
| EP-1485485-A1 | TRANSDIFFERENTIATION OF CELLS AND TISSUES | UNIVERSITY OF BATH (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-20040171034-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. | 2004-09-02 | — | — | US | disclosed |
| EP-1442302-A2 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | Molecular Probes, Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004042347-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | MOLECULAR PROBES, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040038306-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003078636-A1 | TRANSDIFFERENTIATION OF CELLS AND TISSUES | THE UNIVERSITY OF BATH (GB) | 2003-09-25 | — | — | WO | disclosed |
| US-20030135032-A1 | Methods and compositions for bioremediation | IDAHO RESEARCH FOUNDATION | 2003-07-17 | — | — | US | disclosed |
| US-20030100103-A1 | Immunoassay device and immunoassay method using the same | FUJIREBIO INC. (JP) | 2003-05-29 | — | — | US | disclosed |
| US-20030073149-A1 | Antibody complexes and methods for immunolabeling | Life Technologies Corporation | 2003-04-17 | — | — | US | disclosed |
| WO-2003030817-A2 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | MOLECULAR PROBES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1254149-A1 | METHODS AND COMPOSITIONS FOR BIOREMEDIATION | IDAHO RESEARCH FOUNDATION, INC. (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6472160-B2 | APPARATUS FOR ACCURATE ANALYSIS OF VIABLE BODY FLUIDS | FUJIREBIO INC. (JP) | 2002-10-29 | — | — | US | disclosed |
| US-20020045278-A1 | Immunoassay device and immunoassay method using the same | FUJIREBIO INC.(FUJIREBIO KABUSHIKI KAISHA) (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-0762123-B1 | Immunoassay device and immunoassay method using the same | FUJIREBIO KK (JP) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001053309-A1 | METHODS AND COMPOSITIONS FOR BIOREMEDIATION | IDAHO RESEARCH FOUNDATION, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0762123-A1 | Immunoassay device and immunoassay method using the same | FUJIREBIO Inc. (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0762123-A1 | Immunoassay device and immunoassay method using the same | FUJIREBIO Inc. (JP) | 1997-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068748-A1 | Fluorescent Ion Indicators for Cadmium and Lanthanide Ion Detection | SLC30A6, SLC39A14, SLC39A7 | CSNK2A1 4040/4885CYP1A2 4302/4885GSK3B 4680/4885 |
| US-20250152728-A1 | Method And Molecules | PAICS, EPCAM, SQLE | CSNK2A1 3832/4885CYP1A2 239/4885GSK3B 4106/4885 |
| US-20110159517-A1 | Zinc binding compounds and their method of use | SLC30A6, SLC30A7, SLC39A11 | CSNK2A1 3408/4885CYP1A2 4632/4885GSK3B 4622/4885 |
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | DCLRE1A, ACR, PHAX | CSNK2A1 3403/4885CYP1A2 4871/4885GSK3B 4728/4885 |
| US-12102639-B2 | Imipridones for gliomas | HRH3, HTR2A, HTR4 | CSNK2A1 2542/4885CYP1A2 2722/4885GSK3B 1244/4885 |
| US-20190077882-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-20210214419-A1 | METHODS FOR PREPARING ANTIBODIES WITH A DEFINED GLYCOSYLATION PATTERN | FUT6, FUT5, SIGLEC7 | CSNK2A1 2376/4885CYP1A2 4309/4885GSK3B 577/4885 |
| US-20190079095-A1 | COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES | LIG3, LIG1, HLCS | CSNK2A1 3070/4885CYP1A2 1932/4885GSK3B 3781/4885 |
| US-20210236499-A1 | IMIPRIDONES FOR GLIOMAS | HRH3, HTR2A, HTR4 | CSNK2A1 2542/4885CYP1A2 2722/4885GSK3B 1244/4885 |
| US-11116771-B2 | G protein-coupled receptor (GPCR) modulation by imipridones | GCGR, GPR3, GPR132 | CSNK2A1 2502/4885CYP1A2 2091/4885GSK3B 3640/4885 |
| US-20180221375-A1 | IMIPRIDONES FOR GLIOMAS | HRH3, HTR2A, HTR4 | CSNK2A1 2542/4885CYP1A2 2722/4885GSK3B 1244/4885 |
| US-20170304460-A1 | METHOD OF CONJUGATING A POLYPEPTIDE | SHBG, PTMS, VIP | CSNK2A1 1064/4885CYP1A2 2302/4885GSK3B 4710/4885 |
| US-20200206359-A1 | Method And Molecules | PAICS, EPCAM, SQLE | CSNK2A1 3832/4885CYP1A2 239/4885GSK3B 4106/4885 |
| US-20200333351-A1 | Compounds and Methods for Conjugation of Biomolecules | LIG3, LIG1, HLCS | CSNK2A1 3070/4885CYP1A2 1932/4885GSK3B 3781/4885 |
| US-20230321267-A1 | Method And Molecules | PAICS, EPCAM, SQLE | CSNK2A1 3832/4885CYP1A2 239/4885GSK3B 4106/4885 |
| US-20200216871-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | CSNK2A1 1183/4885CYP1A2 4153/4885GSK3B 4724/4885 |
| US-20190307751-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | GCGR, GPR3, GPR132 | CSNK2A1 2502/4885CYP1A2 2091/4885GSK3B 3640/4885 |
| US-20240101712-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-12391768-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-11067580-B2 | Compounds and methods for conjugation of biomolecules | LIG3, LIG1, HLCS | CSNK2A1 3070/4885CYP1A2 1932/4885GSK3B 3781/4885 |
| US-20150355186-A1 | Labeling Reagents and Methods of Their Use | GUSB, CES2, MRPL21 | CSNK2A1 3051/4885CYP1A2 599/4885GSK3B 4262/4885 |
| US-20260132214-A1 | GLYPICAN 3 ANTIBODY AND RELATED METHODS | IGSF11, IGLV6-57, VSIG8 | CSNK2A1 3597/4885CYP1A2 3495/4885GSK3B 2569/4885 |
| US-11639342-B2 | 1,3-dipolar cycloadditions, and Staudinger ligations for conjugating biomolecules using click chemistry | LIG1, TIE1, ALDH1B1 | CSNK2A1 1619/4885CYP1A2 2346/4885GSK3B 4243/4885 |
| US-20190183895-A1 | IMIPRIDONES FOR GLIOMAS | HRH3, HTR2A, HTR4 | CSNK2A1 2542/4885CYP1A2 2722/4885GSK3B 1244/4885 |
| US-11759526-B2 | Method and molecules | PAICS, EPCAM, SQLE | CSNK2A1 3832/4885CYP1A2 239/4885GSK3B 4106/4885 |
| US-20050250214-A1 | Zinc binding compounds and their method of use | SLC30A6, SLC30A7, SLC39A11 | CSNK2A1 3097/4885CYP1A2 4645/4885GSK3B 4610/4885 |
| US-10946022-B2 | Imipridones for gliomas | HRH3, HTR2A, HTR4 | CSNK2A1 2542/4885CYP1A2 2722/4885GSK3B 1244/4885 |
| US-11773186-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-20220160882-A1 | METHOD OF CONJUGATING A POLYPEPTIDE | ZYX, QPCT, MRPL21 | CSNK2A1 1337/4885CYP1A2 3569/4885GSK3B 4571/4885 |
| US-20070161112-A1 | HEAVY METAL BINDING COMPOUNDS AND THEIR METHOD OF USE | SLC30A6, SLC30A5, SLC30A7 | CSNK2A1 4240/4885CYP1A2 1805/4885GSK3B 4708/4885 |
| US-20100167333-A1 | Heavy Metal Binding Compounds and Their Method of Use | SLC30A6, SLC30A5, SLC30A7 | CSNK2A1 4240/4885CYP1A2 1805/4885GSK3B 4708/4885 |
| US-10648985-B2 | Compounds and methods for conjugation of biomolecules | LIG3, LIG1, HLCS | CSNK2A1 3070/4885CYP1A2 1932/4885GSK3B 3781/4885 |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | CSNK2A1 1183/4885CYP1A2 4153/4885GSK3B 4724/4885 |
| US-20130089884-A1 | Protein Modification from the Oxidation of Clickable Polyunsaturated Fatty Acid Analogs | FASN, ACSL6, FADS1 | CSNK2A1 1928/4885CYP1A2 3334/4885GSK3B 4697/4885 |
| US-20150072396-A1 | Compounds and Methods for Conjugation of Biomolecules | LIG3, LIG1, HLCS | CSNK2A1 3070/4885CYP1A2 1932/4885GSK3B 3781/4885 |
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-10172862-B2 | Imipridones for gliomas | HRH3, HTR2A, HTR4 | CSNK2A1 2542/4885CYP1A2 2722/4885GSK3B 1244/4885 |
| US-10369154-B2 | Imipridones for gliomas | HRH3, HTR2A, HTR4 | CSNK2A1 2542/4885CYP1A2 2722/4885GSK3B 1244/4885 |
| US-20210214338-A1 | 1,3-DIPOLAR CYCLOADDITIONS, AND STAUDINGER LIGATIONS FOR CONJUGATING BIOMOLECULES USING CLICK CHEMISTRY | LIG1, TIE1, ALDH1B1 | CSNK2A1 1619/4885CYP1A2 2346/4885GSK3B 4243/4885 |
| US-20220072001-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | GCGR, GPR3, GPR132 | CSNK2A1 2502/4885CYP1A2 2091/4885GSK3B 3640/4885 |
| US-20160257732-A1 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | H1-3, H1-4, H1-5 | CSNK2A1 2562/4885CYP1A2 3786/4885GSK3B 1797/4885 |
| US-11414477-B2 | Methods for preparing antibodies with a defined glycosylation pattern | FUT6, FUT5, SIGLEC7 | CSNK2A1 2376/4885CYP1A2 4309/4885GSK3B 577/4885 |
| US-20050250957-A1 | Compounds containing thiosulfate moieties | TST, MPST, STS | CSNK2A1 2750/4885CYP1A2 1959/4885GSK3B 4716/4885 |
| US-20180319897-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-20160130366-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-20240366613-A1 | IMPRIDONES FOR GLIOMAS | GRM3, HRH3, HTR2A | CSNK2A1 2224/4885CYP1A2 2588/4885GSK3B 1129/4885 |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | CSNK2A1 1183/4885CYP1A2 4153/4885GSK3B 4724/4885 |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | CSNK2A1 4468/4885CYP1A2 946/4885GSK3B 2799/4885 |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | RNGTT, ADAR, ALKBH1 | CSNK2A1 2021/4885CYP1A2 2155/4885GSK3B 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.